Ekf Diagnostics Regulatory News (EKF)

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Mike Salter, CEO

 Tel: +44 (0)29 2071 0570

Marc Davies, CFO

Singer Capital Markets (Nominated Adviser & Joint Broker)

Tel: +44 (0)20 7496 3000

Aubrey Powell / George Tzimas

Investec Bank plc (Joint Broker)

Tel: +44 (0)20 7597 4000

Gary Clarence / Daniel Adams / Ben Farrow

Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com 

Paul McManus / Lianne Applegarth

Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Julian Baines

2

Reason for the notification

a)

Position/status

Non-Executive Deputy Chairman

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

EKF Diagnostics Holdings plc

b)

LEI

213800DXTF3EAUK1AR05

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

Identification code

GB0031509804

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

32.596 pence

11,000

d)

Aggregated information

- Aggregated volume

N/A - Single Transaction

- Price

e)

Date of the transaction

20 June 2022

f)

Place of the transaction

London Stock Exchange - AIMX

Point-of-Care

Providing a portfolio of Point-of-Care analysers and consumables, particularly for use in the area of Hematology and Diabetes, for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF has an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries.

Central Laboratory

Clinical chemistry, Small lab analysers, Centrifuges

Beta-Hydroxybutyrate (β-HB) LiquiColor, Glycates Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin

Life Sciences

Enzyme fermentation, Custom products and Bulk fermentation

Contract Manufacturing 

Bulk formulation, Sample collection kits, Private labelling, Molecular and forensic kits

Laboratory Services

In September 2021, EKF completed the acquisition of Advanced Diagnostic Laboratory LLC ("ADL Health"), a Texas based testing laboratory certified under the Clinical Laboratory Improvement Amendments ("CLIA") for high complexity testing. The laboratory provides testing for a variety of clinical, forensic and microbiological sample types using a range of analytical techniques. This acquisition positions EKF as a leading 'one stop' provider of diagnostic products and services from sample collection to results.

•

continuing innovation in products and services in Point-of-Care, Central Laboratory and Life Sciences leveraging new and existing routes to market and relationships;

•

investment in expanded production and kitting capabilities to offer a suite of diagnostic Contract Manufacturing solutions to third party businesses;

•

expansion of CLIA Laboratories Testing offering, building on the acquired capabilities in ADL Health; and

•

concluding complementary earnings-enhancing acquisitions with key strategic value.

•

a progressive dividend policy; and

•

its agreement with Mount Sinai Innovation Partners ("MSIP"), which allows us advanced access to innovative commercial opportunities and where we can build on the ongoing successes of Renalytix plc, Verici Dx plc and Trellus Health plc.